CN101878203A - 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物 - Google Patents

作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物 Download PDF

Info

Publication number
CN101878203A
CN101878203A CN200880118458XA CN200880118458A CN101878203A CN 101878203 A CN101878203 A CN 101878203A CN 200880118458X A CN200880118458X A CN 200880118458XA CN 200880118458 A CN200880118458 A CN 200880118458A CN 101878203 A CN101878203 A CN 101878203A
Authority
CN
China
Prior art keywords
formula
compound
tetrazol
quinazoline
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880118458XA
Other languages
English (en)
Chinese (zh)
Inventor
杜加·普拉萨德·康纳康驰
苏巴·劳·普拉
拉克西米·安南特内利
穆达萨尼·普拉雷迪
布疆加·劳·阿迪巴特拉卡利萨蒂亚
纳纳潘尼·委卡拉筹德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Natco Pharma Ltd
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of CN101878203A publication Critical patent/CN101878203A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880118458XA 2007-10-29 2008-10-28 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物 Pending CN101878203A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2445CH2007 2007-10-29
IN2445/CHE/2007 2007-10-29
PCT/IN2008/000708 WO2009057139A2 (en) 2007-10-29 2008-10-28 Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents

Publications (1)

Publication Number Publication Date
CN101878203A true CN101878203A (zh) 2010-11-03

Family

ID=40433677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880118458XA Pending CN101878203A (zh) 2007-10-29 2008-10-28 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物

Country Status (15)

Country Link
US (1) US8080558B2 (enExample)
EP (1) EP2220054A2 (enExample)
JP (1) JP2011502141A (enExample)
KR (1) KR20100087185A (enExample)
CN (1) CN101878203A (enExample)
AU (1) AU2008320342B2 (enExample)
CA (1) CA2703767A1 (enExample)
EA (1) EA018716B1 (enExample)
GE (1) GEP20125603B (enExample)
MX (1) MX2010004625A (enExample)
MY (1) MY150054A (enExample)
NZ (1) NZ585357A (enExample)
UA (1) UA101168C2 (enExample)
WO (1) WO2009057139A2 (enExample)
ZA (1) ZA201002807B (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130729A (zh) * 2011-12-05 2013-06-05 齐鲁制药有限公司 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103204817A (zh) * 2013-04-16 2013-07-17 江西师范大学 4-氰基喹唑啉衍生物的制备方法
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉
WO2016150340A1 (zh) * 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
CN114437041A (zh) * 2022-02-25 2022-05-06 湖北科技学院 一类具有抗肿瘤活性的4-四唑基取代-3，4-二氢喹唑啉衍生物及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039714A2 (en) * 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN102993114B (zh) * 2012-10-11 2015-08-12 南通市华峰化工有限责任公司 一种1h-四唑-5-乙酸的生产方法
CN114787151B (zh) * 2019-11-01 2024-04-16 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐、或其药物组合物的用途
JP2023549973A (ja) * 2020-11-23 2023-11-29 エフ． ホフマン－ラ ロシュ アーゲー テトラゾール誘導体の製造のための新規方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800039A (en) * 1970-10-21 1974-03-26 Mead Johnson & Co Antithrombogenic process employing substituted 6,7-dialkoxyquinazolines
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
AU632992B2 (en) 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
DE3917982A1 (de) 1989-06-02 1990-12-06 Behringwerke Ag Verwendung von xylanpolyhydrogensulfaten zur therapie von zellproliferations-bedingten erkrankungen
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DE69718472T2 (de) 1996-07-13 2003-11-06 Glaxo Group Ltd., Greenford Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
GB0002040D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
DE10042059A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
JP2005515176A (ja) 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
PL371587A1 (en) * 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4611745B2 (ja) 2002-11-20 2011-01-12 アレイ バイオファーマ、インコーポレイテッド ＥｒｂＢ２及びＥＧＦＲ阻害剤としてのシアノグアニジン及びシアノアミジン
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
CN101490016A (zh) * 2006-07-28 2009-07-22 诺瓦提斯公司 作为脂激酶抑制剂的2,4-取代的喹唑啉

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130729B (zh) * 2011-12-05 2015-07-15 齐鲁制药有限公司 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103130729A (zh) * 2011-12-05 2013-06-05 齐鲁制药有限公司 一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103204817B (zh) * 2013-04-16 2018-03-27 江西师范大学 4‑氰基喹唑啉衍生物的制备方法
CN103204817A (zh) * 2013-04-16 2013-07-17 江西师范大学 4-氰基喹唑啉衍生物的制备方法
CN105358552A (zh) * 2013-05-11 2016-02-24 默克专利股份公司 芳基喹唑啉
CN105358552B (zh) * 2013-05-11 2018-04-27 默克专利股份公司 芳基喹唑啉
CN107406430A (zh) * 2015-03-20 2017-11-28 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
WO2016150340A1 (zh) * 2015-03-20 2016-09-29 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
US10231973B2 (en) 2015-03-20 2019-03-19 Chai Tai Tianqing Pharmaceutical Group Co., Ltd. Salts of quinazoline derivative and method for preparing the same
CN107406430B (zh) * 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
RU2720810C2 (ru) * 2015-03-20 2020-05-13 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Соли производного хиназолина и способ их получения
CN114437041A (zh) * 2022-02-25 2022-05-06 湖北科技学院 一类具有抗肿瘤活性的4-四唑基取代-3，4-二氢喹唑啉衍生物及其制备方法和应用
CN114437041B (zh) * 2022-02-25 2023-11-10 湖北科技学院 一类具有抗肿瘤活性的4-四唑基取代-3，4-二氢喹唑啉衍生物及其制备方法和应用

Also Published As

Publication number Publication date
AU2008320342A1 (en) 2009-05-07
CA2703767A1 (en) 2009-05-07
KR20100087185A (ko) 2010-08-03
US20100261740A1 (en) 2010-10-14
UA101168C2 (ru) 2013-03-11
EA201070543A1 (ru) 2010-12-30
EP2220054A2 (en) 2010-08-25
NZ585357A (en) 2012-02-24
AU2008320342B2 (en) 2012-07-26
JP2011502141A (ja) 2011-01-20
MX2010004625A (es) 2010-05-20
MY150054A (en) 2013-11-29
EA018716B1 (ru) 2013-10-30
WO2009057139A2 (en) 2009-05-07
WO2009057139A3 (en) 2009-09-24
ZA201002807B (en) 2011-07-27
US8080558B2 (en) 2011-12-20
AU2008320342A2 (en) 2010-09-02
GEP20125603B (en) 2012-08-10

Similar Documents

Publication Publication Date Title
EP2163546B1 (en) Quinazoline derivatives
JP3545763B2 (ja) キナゾリン誘導体及びその抗癌剤としての使用
CN101878203A (zh) 作为抗癌剂的新的4-(四唑-5-基)喹唑啉衍生物
US5747498A (en) Alkynyl and azido-substituted 4-anilinoquinazolines
JP3457164B2 (ja) アミノキナゾリン誘導体
Trinks et al. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase
ZA200402995B (en) Salt forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer.
TW200301121A (en) Small molecules for the treatment of abnormal cell growth
CZ299561B6 (cs) Chinazolinaminový derivát a farmaceutický prostredek
JPH11504032A (ja) キナゾリン誘導体
WO2009109991A2 (en) Novel hydrazide containing tyrosine kinase inhibitors
CN118652239A (zh) 一类egfr别构抑制剂的合成及其用途
US20120172380A1 (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agent
CN110078712A (zh) 一类含有氨基咪唑基化合物、其药物组合物和用途
HK1231045A (en) Quinazoline derivatives
HK1231045A1 (en) Quinazoline derivatives
HK1141804A (en) Quinazoline derivatives
HK1042083A (en) Quinazoline derivatives
AU7939101A (en) Intermediates for the preparation of 4-(substituted phenylamino)quinazoline derivatives
HK1071743A (en) Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101103